Roth Capital began coverage on shares of Conatus Pharmaceuticals (NASDAQ:CNAT) in a research report released on Thursday, MarketBeat reports. The firm issued a buy rating and a $20.00 target price on the biotechnology company’s stock.

A number of other research firms have also recently commented on CNAT. S&P Equity Research increased their price target on Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th. Zacks Investment Research cut Conatus Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, January 22nd. Finally, HC Wainwright reiterated a buy rating and issued a $17.00 price target (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $13.67.

Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at $5.06 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. The firm has a market capitalization of $151.83, a price-to-earnings ratio of -6.25 and a beta of 1.25. Conatus Pharmaceuticals has a 12 month low of $3.88 and a 12 month high of $9.40.

A number of institutional investors have recently added to or reduced their stakes in the business. MPM Asset Management LLC raised its stake in Conatus Pharmaceuticals by 76.3% in the fourth quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock valued at $9,707,000 after buying an additional 909,091 shares during the last quarter. BlackRock Inc. raised its stake in Conatus Pharmaceuticals by 6.2% in the fourth quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock valued at $7,362,000 after buying an additional 93,015 shares during the last quarter. Vanguard Group Inc. raised its stake in Conatus Pharmaceuticals by 31.2% in the second quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after buying an additional 239,373 shares during the last quarter. State Street Corp purchased a new stake in Conatus Pharmaceuticals in the second quarter valued at about $2,092,000. Finally, Northern Trust Corp raised its stake in Conatus Pharmaceuticals by 640.6% in the second quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after buying an additional 257,030 shares during the last quarter. Institutional investors own 35.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Roth Capital Initiates Coverage on Conatus Pharmaceuticals (CNAT)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/11/roth-capital-initiates-coverage-on-conatus-pharmaceuticals-cnat.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.